Dapirolizumab pegol

Generic Name
Dapirolizumab pegol
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1416147-64-2
Unique Ingredient Identifier
N4606MB5HM
Background

Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).

Associated Conditions
-
Associated Therapies
-
investing.com
·

Biogen stock hits 52-week low at $181.25 amid market challenges

Biogen Inc. stock hit a 52-week low of $181.25, reflecting a -24.53% 1-year change. Despite market challenges, Biogen reported Q2 revenue of $2.5 billion, received FDA Breakthrough Therapy Designation for felzartamab, and presented positive DEVOTE study results. Collaborations with UCB and Samsung Bioepis yielded successful trial and regulatory milestones. Biogen's strong financial position, with a 76.45% gross profit margin, and analyst Outperform ratings suggest resilience amidst volatility.
prnewswire.com
·

The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol

UCB and Biogen report positive Phase III PHOENYCS GO trial results for dapirolizumab pegol in moderate-to-severe SLE, with a second Phase 3 trial, PHOENYCS FLY, planned for 2024. The SLE market is expected to grow from USD 3.2 billion in 2023, driven by emerging therapies like Litifilimab, Ianalumab, and Cenerimod.
biospace.com
·

Kezar's Lupus Trial Paused After Four Patient Deaths

FDA placed a clinical hold on Kezar Life Sciences' zetomipzomib development for lupus nephritis after 4 patients died in Phase IIb PALIZADE trial. Kezar observed common symptoms and proximity to dosing in the deaths and other serious adverse events, leading to voluntary suspension of enrollment and dosing. The company is investigating potential risk mitigation strategies and expects a formal FDA letter. Kezar continues zetomipzomib development for autoimmune hepatitis unaffected by the hold.
dailymail.co.uk
·

New drug to combat debilitating immune system disorder lupus - the condition that left Seal scarred

A new lupus drug, dapirolizumab pegol, shows 'substantial improvement' in most patients, potentially available on the NHS. Lupus affects 50,000 Britons, causing skin rashes, joint pain, and kidney problems, with Seal as a notable sufferer. The once-a-month injection could be a first-of-its-kind treatment, according to Dr. Ed Vital.
biospace.com
·

Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data

Genentech announced Gazyva met primary efficacy endpoint in Phase III REGENCY study for lupus nephritis, showing statistically significant and clinically meaningful benefits. Gazyva, a monoclonal antibody targeting CD20, also met key secondary endpoints, including reduction in corticosteroid use and improvement in proteinuric response. Roche plans to present data to FDA and other health authorities for potential approvals.

Dapirolizumab Pegol Looks Promising for Systemic Lupus Erythematosus

Phase 3 trial of dapirolizumab pegol in moderate to severe SLE met primary endpoint, showing significant clinical improvement vs placebo. Secondary endpoints also met, indicating potential benefit in SLE treatment.
geneonline.com
·

Biogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another

Biogen and UCB report promising Phase-III trial data for lupus treatment, dapirolizumab pegol, potentially reshaping the market. UC Davis Health explores CAR T-cell therapy as an alternative for lupus and lupus nephritis, aiming for targeted treatment.
hcplive.com
·

Dapirolizumab Pegol Meets Primary Endpoint in Phase 3 Study for SLE

The phase 3 PHOENYCS GO study met its primary endpoint, showing clinical improvement in moderate-to-severe systemic lupus erythematosus (SLE) patients treated with dapirolizumab pegol plus standard-of-care. UCB and Biogen plan to initiate a second phase 3 study in 2024, with further data to be presented at a future medical meeting.

UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released

UCB and Biogen's lupus drug, dapirolizumab pegol, met primary endpoint in Phase III PHOENYCS GO trial, showing improvement in moderate-to-severe SLE. The drug also demonstrated clinical improvements in secondary endpoints and a consistent safety profile. UCB's stock rose 2.57% post-announcement. Detailed data will be presented at an upcoming medical conference.
© Copyright 2024. All Rights Reserved by MedPath